Alzheimer's Research and Treatment Center

Lake Worth, Florida 33449

0 studies enrolling now · 15 studies all time

What they study most

Agitation in Participants With Dementia of the Alzheimer's Type, Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Alzheimer's Disease, Alzheimer´s Disease, Early Alzheimer's Disease

Studies at this site

• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease — Running, not enrolling
• Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type — Completed
• GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease — Completed
• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type — Completed
• Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance — Stopped early
• AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext — Completed
• A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine — Completed
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early
• A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) — Stopped early
• An Open-Label Crenezumab Study in Participants With Alzheimer's Disease — Stopped early
• An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease — Stopped early
• Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease — Completed
• A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease — Completed
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease — Completed
• Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease — Completed